CDE accepts IND application for Reforgene's novel-target thalassemia gene editing medicine
On August 15, 2022, the IND application for RM001, Reforgene's independently developed beta-thalassemia ex vivo gene editing medicine, was accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (Acceptance No.: CXSL2200378). RM001 is China's first gene editing product with a novel HBG target, for the treatment of beta-thalassemia.
The RM001 product uses CRISPR/Cas gene editing technology to permanently modify the gamma-globin promoter, activating the body's natural fetal hemoglobin synthesis, restoring normal physiological function of red blood cells and freeing patients from blood transfusion, achieving the goal of a one-time administration to cure beta-thalassemia. In early clinical research, Reforgene used HBG novel-target gene editing therapy for the first time in the world to successfully cure 5 patients with transfusion-dependent beta-thalassemia, including one adult patient, achieving excellent treatment results. The preliminary clinical research data were reported at the 27th European Hematology Association Congress (27th EHA Congress) in 2022.
About thalassemia
Thalassemia is the monogenic genetic disease with the widest affected population worldwide. As an inherited blood disease, it is named after its high incidence in the countries along the Mediterranean coast. There remains a huge unmet need in thalassemia treatment, with a lack of universally applicable curative medicines. In China, thalassemia is concentrated in 10 provinces south of the Yangtze River, including Guangdong, Guangxi, Hainan, Fujian and Yunnan. The 2015 China Thalassemia Blue Book research report shows that there are more than 345 million thalassemia gene carriers worldwide, with 30 million carriers in China. The severe genetic burden of thalassemia affects the health and quality of life of the Chinese people. Among them, transfusion-dependent patients require long-term blood transfusion and iron chelation treatment, with long-term organ damage, shorter life expectancy and a significantly higher mortality rate than the normal population.
About Reforgene
Reforgene Medicine is one of China's leading innovative gene editing drug companies, driven by gene editing technology and dedicated to bringing novel medicines to life. The company has pipeline programs across genetic diseases and complex diseases. Its innovative beta-thalassemia medicine has achieved globally leading clinical progress, and it achieved the world's first cure of an alpha-thalassemia patient.
Media Contact
info@reforgene.com
Forward-Looking Statements
Reports, articles and other content published on this website may contain forward-looking statements relating to Reforgene Medicine ("the Company") and the gene editing and biopharmaceutical industries. These statements may address, among other things, the Company's strategy, research and development, product pipeline and related progress, clinical research, regulatory submissions and approvals, manufacturing, supply and commercialization, collaborations and licensing, as well as industry trends, market size and technological developments. Forward-looking statements can often be identified by words such as "anticipate," "expect," "plan," "intend," "aim," "may," "will," "continue," or similar expressions. They reflect the views of the party making the statement, based on information available as of the date of publication and the expectations and assumptions then held, and are not statements of historical fact.
Statements made or provided by the Company represent the Company's views. Statements made or republished by third-party media, research institutions, experts or other parties represent only the views of those parties and do not necessarily represent the Company's position. Forward-looking statements are subject to known and unknown risks and uncertainties, including but not limited to those relating to research and technology, safety and efficacy, clinical trials, regulatory review and approval, manufacturing and supply, commercialization, collaborations and licensing, intellectual property, competition, laws and regulations, and macroeconomic conditions. Actual results, progress in research or commercialization, and the timing of events may differ materially from those expressed or implied by such statements. Readers should not place undue reliance on forward-looking statements, and past performance is not indicative of future results.
Except as required by law or regulatory requirements, the Company undertakes no obligation to update or revise any forward-looking statements made by it and gives no assurance that they will be realized. Third-party statements are the responsibility of their original publishers. This notice does not constitute investment advice or an offer or solicitation for the subscription, purchase or sale of any securities.